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Electronic Compliance Assessment of Antifungal Prophylaxis for
Human Immunodeficiency Virus-Infected Women
SANDRA M. GELETKO,1,2* MARISEL SEGARRA,1,2† KENNETH H. MAYER,3,4 THERESA C. FIORE,4,5
FRANCES A. BETTENCOURT,3,4 TIMOTHY P. FLANIGAN,4,5 AND MICHAEL N. DUDLEY1,6
Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, Rhode Island 02881-08091;
Veterans Affairs Medical Center2 and Roger Williams Medical Center,6 Providence, Rhode Island 02908;
Memorial Hospital of Rhode Island, Pawtucket, Rhode Island 028603; and Brown University
AIDS Program4 and The Miriam Hospital,5 Providence, Rhode Island 02906

Several prophylactic medications for opportunistic or recurrent infections are used in human immunodeficiency virus-infected individuals. Essential to the efficacy evaluation of these agents is the accurate reporting
of medication compliance. We hypothesized that poor patient compliance with thrice-weekly fluconazole
prophylaxis would correlate with the occurrence of clinical events. Fluconazole compliance was monitored
electronically by using the Medication Event Monitoring Systems with 19 women receiving fluconazole at 50 mg
thrice weekly for prophylaxis of recurrent mucocutaneous candidiasis. During 202 patient-months of follow-up,
eight breakthrough episodes of mucocutaneous candidiasis developed in four women; compliance data were
available for seven of these episodes. At 6 months of therapy, more women with greater than or equal to 80%
compliance were disease free compared with women with less than 80% compliance (P < 0.05; the Fisher exact
test). These data suggest that documentation of medication compliance is essential in studies of chronic
prophylaxis in human immunodeficiency virus-infected patients to properly evaluate drug efficacy and to avoid
erroneous conclusions concerning drug failure.
days prior to testing of the drug level in serum. MEMS have
the additional advantage of reporting the length of time between scheduled doses (14). With the increasing rise in the
number of women with human immunodeficiency virus (HIV)
infection, an understanding of the unique health care needs of
women and their obstacles to the provision of health care is
essential, including assessment of medication compliance. Furthermore, medication noncompliance can obfuscate the assessment of the efficacy of a prophylactic medication. The purpose
of the study described here was to electronically monitor
thrice-weekly fluconazole dosing events during a clinical trial
with HIV-infected women in order to assess the influence of
compliance on clinical events.

Noncompliance with drug therapy may lead to the increased
use of health care resources and reduced quality of life. It has
been reported that 11 to 28% of emergency room visits or
hospital admissions are due to medication noncompliance (4,
7, 13). One meta-analysis estimated that the annual cost of
medication noncompliance is approximately $8.5 billion (17).
Several methods for the assessment of medication compliance
have been used in clinical settings as well as in clinical trials.
These methods include monitoring of the level of the drug in
the patient’s blood, measurement of drug excretion in urine,
pill counts, patient questionnaires, observation of therapeutic
outcome, and the presence of side effects (5). All of these
methods have certain important limitations. For example, pill
counts may be altered by patients and monitoring of drug
levels in blood and urinary excretion studies are inconvenient,
nonquantitative, and expensive. Single measurements of drug
concentrations in serum are subject to the need for accurate
dosing histories and assumptions concerning steady-state conditions; hence, these measures are not precise assessments of
drug compliance patterns, particularly compliance with drugs
with long half-lives. The Medication Event Monitoring Systems (MEMS) are normal-appearing prescription vials with
caps containing microprocessors which record the date and
time of vial opening. Studies have shown that MEMS can
assess patient compliance with certain medications (3, 14). The
advantage of MEMS compared with other forms of compliance monitoring is the ability to quantitatively assess compliance over prolonged periods of treatment. Other methods,
such as determination of drug levels in serum, only measure
compliance since the preceding dosing interval or the last few

MATERIALS AND METHODS
Trial design. A multicenter, randomized, cross-over study was conducted with
HIV-infected women with CD41 counts of less than 500 cells per mm3 to
determine if fluconazole prophylaxis is effective for the prevention of vaginal,
oropharyngeal, and esophageal candidiases; the preliminary results have been
reported elsewhere (6). HIV-infected women with CD41 counts of less than 500
cells per mm3, over 18 years of age, without a history of systemic fungal disease,
without current mucosal fungal infection, and with transaminase levels less than
five times the upper limit of normal qualified for randomization. Informed
consent was obtained from the patients, and the guidelines for human experimentation of the U.S. Department of Health and Human Services and The
Miriam Hospital and Rhode Island Hospital, Providence, R.I., were followed in
the conduct of the study. Women were randomized to receive either fluconazole
at 50 mg on a Monday, Wednesday, and Friday or to receive no treatment but to
undergo regular observation. A history was taken and a symptom-oriented physical examination was performed every 3 months for all women enrolled in the
study. If women were symptomatic for mucocutaneous candidiasis, a potassium
hydroxide preparation of the potentially infected site was completed. If a breakthrough episode developed while a woman was noncompliant with fluconazole,
the patient was treated with topical antifungal agents; if a breakthrough episode
developed while a women was compliant with thrice-weekly fluconazole, the
patient was treated with a higher daily dose of fluconazole.
Compliance monitoring. MEMS-3 (Aprex Corporation, Fremont, Calif.) was
used to monitor patient compliance. At the time of entry into the trial, patients
randomized to receive fluconazole were dispensed a 3-month supply of fluconazole in a MEMS vial. The patients were informed that the cap contained a
computer chip for the purpose of recording the timing of dosing, but it was
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TABLE 1. Demographic data for 15 women without and 4 women
with resulting episodes during fluconazole prophylaxisa
Value
Characteristic

15 women without 4 women with
breakthroughs
breakthroughs

30
24–45

37.5
28–40

Race (no. [%])
Caucasian
Hispanic

12 (80)
3 (20)

2 (50)
2 (50)

7 (47)
5 (33)
2 (13)
1 (7)

2 (50)
2 (50)
0 (0)
0 (0)

Duration of HIV seropositivity (yr)
Median
Range

3
1–6

3

Diagnosis of AIDS (no. [%])

1 (7)

1 (25)

Prophylactic antibiotic use (co-trimoxazole or dapsone) (no. [%])

3 (20)

2 (50)

Antiretroviral therapy (no. [%])

14 (93)

4 (100)

Prior episodes of candidiasis (no. [%])

11 (73)

4 (100)

Transmission risk group (no. [%])
IVDU or heterosexual contact
IVDU (no. [%])
Heterosexual contact (no. [%])
IVDU or contact with blood products (no. [%])

a

3–6

No difference between groups by Fisher’s exact test.

stressed that dosing readings would not threaten their status in the study. Patients were instructed to keep the fluconazole in the MEMS vial and not to
remove the drug and put it in another container. At every 3-month follow-up
visit, a clinical pharmacist transferred the information from the MEMS cap to a
laptop computer using the appropriate software, and an additional 3-month
supply of fluconazole was dispensed in the same MEMS vial.
Data analysis. Medication events were quantitatively calculated per week, with
100% compliance considered three vial openings per week. Qualitative compliance (i.e., doses taken on Monday, Wednesday, and Friday, as prescribed) was
similar to the quantitative compliance and was not incorporated into the present
analysis. A quantitative value of greater than 80% compliance was classified as
good compliance, as previously defined by others (1, 15). Failure of therapy was
concluded when a patient either developed a documented episode of mucocutaneous candidiasis or dropped out of the study. Treatment failure after 6
months of therapy was compared in women with greater than 80% compliance
versus those with less than 80% compliance by Kaplan-Meier analysis and the
Fisher exact test (9, 11, 16, 17).

RESULTS
Electronic compliance data were available for 19 patients
monitored for 202 patient-months. Table 1 provides the characteristics of the patients. Most women were Caucasian and
identified intravenous drug use (IVDU) as one risk factor for
HIV transmission. A minority of women were diagnosed with
AIDS. The reasons for patient attrition from the study included IVDU, pregnancy, lack of desire to take another medication, medication side effects, breakthrough infections, or
death.
Eight episodes of mucocutaneous candidiasis occurred in
four patients during the period of monitoring with MEMS,
with compliance information available for seven of these episodes. Figure 1 displays the biweekly compliance by the 15
women without breakthrough episodes and each of the 4
women who developed breakthrough episodes.

Patient 1. Two episodes of documented vaginal candidiasis
occurred in weeks 20 and 24 in patient 1. In both episodes, a
period of significant noncompliance was observed prior to or at
the time of breakthrough.
Patient 2. Patient 2 experienced a symptomatic, KOH-positive episode of vaginal candidiasis after 6 weeks of fluconazole
prophylaxis. The patient appeared to be compliant with the
regimen by MEMS recordings. Despite poor compliance after
this single episode, no further episodes of vaginal candidiasis
occurred in this patient. This patient’s CD41 count remained
at between 100 and 200 cells per mm3 during the study period.
Patient 3. Esophageal candidiasis developed in patient 3
after 23 months of fluconazole prophylaxis. The pattern of
fluconazole use in this patient over the preceding 3 months
showed erratic drug administration. Furthermore, this patient’s most recent CD41 count 10 months before the candidal
infection was 70 cells per mm3.
Patient 4. Three episodes of mucocutaneous candidiasis occurred in patient 4 during prophylaxis. Two breakthrough episodes appeared to be related to noncompliance. The third
episode in this patient occurred while the patient was compliant, but her CD41 count had recently dropped below 50 cells
per mm3.
Analysis of compliance. Compliance over the entire study
period was analyzed by grouping the women according to
whether or not they were greater than or equal to 80% compliant. Figure 2 shows that the time to treatment failure was
significantly shorter for women with less than 80% compliance
compared with that for women with greater than or equal to
80% compliance. The median time to the first breakthrough
infection was 19 weeks. At 6 months of treatment, significantly
more women with less than 80% compliance had failed treatment than women with greater than 80% compliance (P ,
0.05; the Fisher exact test).
DISCUSSION
In the present study of 19 women receiving fluconazole
prophylaxis, eight breakthrough episodes of mucocutaneous
candidiasis occurred in four women. Because of the low number of breakthrough episodes, we cannot definitely associate
noncompliance with breakthrough episodes. In some study
patients (e.g., patient 2), there were no breakthrough episodes
during prolonged periods of noncompliance. While noncompliance immediately preceding a breakthrough event did not
occur in every instance, it does appear that women with an
overall higher level of compliance (greater than 80%) experienced a longer disease-free period than women with an overall
lower level of compliance (less than 80%). Advanced immunosuppression, as suggested by markedly decreased CD41
counts, may have predisposed even a compliant patient to a
breakthrough infection. Although medication resistance could
have contributed to the breakthrough episodes in some of
these women, this hypothesis cannot be confirmed since the
organisms isolated were not tested for their susceptibilities to
fluconazole.
Assurance of medication compliance and the degree of medication compliance are crucial for the proper assessment of the
efficacies of new treatment approaches. In studies of oral trimethoprim-sulfamethoxazole in the prevention of infection in
neutropenic patients, good medication compliance was associated with a significant reduction in the incidence of fever or
infection compared with the incidence in placebo-treated patients (12). When both compliant and noncompliant patients
were combined, there was no significant difference in infection
rates between placebo and trimethoprim-sulfamethoxazole-
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FIG. 1. Average number of openings in a 2-week period recorded by MEMS for study patients on thrice-weekly fluconazole therapy. Arrows indicate when
breakthrough events occurred. Dashed lines indicate 100% compliance (three recorded openings per week).
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opment, it is essential to confirm patient compliance in these
situations (10). In addition to erroneously assuming drug failure, noncompliance during clinical trials can lead to overestimation of the optimal dose of a medication (8). In the present
study, electronic compliance monitoring provided data on both
overall compliance and the specific patterns of drug use, which
were necessary to determine an association with breakthrough
infections. Implementation of strategies to enhance medication compliance may improve patient outcomes as a result of
the use of prophylaxis in this population and reduce the cost of
care for these patients.
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FIG. 2. Kaplan-Meier analysis according to average compliance with thriceweekly fluconazole therapy (P , 0.001, log-rank test). {, patients with $80%
compliance; }, patients with ,80% compliance.
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